Mu.Ta.Lig - COST ACTION CA15135

Dr. Akram ALIAN

14 June 2016


General information

Name: Akram
Surname: Alian
Cell phone number with international prefix: +972-55-666-4838
Country: Israel
Affiliation: Technion – Israel Institute of Technology
Gender: M
Year of the PhD title: 2002
Personal web page:
Previous COST participation: Yes


List of 10 selected publications within last 5 years

1. Marx A. Galilee M. and Alian A. Zinc enhancement of cytidine deaminase activity highlights a potential allosteric role of loop-3 in regulating APOBEC3 enzymes. 2015 Scientific Reports, 5: 18191
2. Eliahoo E., Marx A., Manor H., and Alian A. A Novel Open-Barrel Structure of Octameric Translin Reveals a Potential RNA Entryway. 2015 J. Mol. Biol., 427: 756-762.
3. Marx A. and Alian A. The first crystal structure of a dTTP bound deoxycytidylate deaminase validates and details the allosteric-inhibitor binding site. 2015 J. Biol. Chem.. 290: 682-690
4. Galilee A. and Alian A. Identification of Phe187 as a Crucial Dimerization Determinant Facilitates Crystallization of a Monomeric Retroviral Integrase Core Domain. 2014, Structure, 22: 1512-1519.
5. Czudnochowski N, Ashley G, Santi D, Alian A, Finer-Moore J, and Stroud RM. The mechanism of pseudouridine synthases from a covalent complex with RNA, and alternate specificity for U2605 versus U2604 between close homologs. 2014, Nucleic Acids Res., 42: 2037-2048
6. Wu S, Avila-Sakar A, Kim J, Booth DS, Greenberg CH, Rossi A, Liao M, Alian A, Griner SL, Juge N, Yu Y, Merge CM, Chaparro-Riggers J, Strop P, Tampé R, Edwards RH, Stroud RM, Craik CS, Cheng Y. Fabs enable high-resolution single particle cryoEM studies of small proteins. 2012, Structure, 20: 582-592.
7. Marx A. and Alian A. Rerouting Resistance: Escaping Restriction Using Alternative Cellular Pathways. 2015 Trends in Microbiology, 23: 595-597.
8. Marx A. and Alian A. The road less traveled: HIV’s use of alternative routes through cellular pathways. 2015 Journal of Virology, 89: 5204-5212.
9. Alian A. and Aqeilan RI. T538 phosphorylation, Pin-ing p63-Itch stability. 2015 Cell Cycle, 15:0
10. Zaidoun S, Alian A, and Aqeilan RI. WW domain-containing proteins: Retrospectives and the future. 2012 Front. Biosci., 17: 331-348.




Main skills and expertise (up to 5)

1. Macromolecule X-ray Crystallography
2. Biochemistry (protein chromatography, enzymatic activities)
3. Protein-ligand (DNA/RNA, small molecule, protein complexes) interactions (pull down, chromatography, FRET, MST thermophoresis, ITC, TSA-Thermofluorescence)
4. Retrovirology; DNA/RNA modifying enzymes (methylation, peudouridination); enzyme-substrate specificity; structure-function relationship


Main equipment/facilities available in the participants’ lab (up to 5)

1. X-ray crystallography (TTP Mosquito drop dispenser; Rigaku FRX X-ray diffractormeter)
2. Molecular interactions (Monolith ITC; NanoTemp MST thermophoresis)
3. Molecular Biology (PCR, Western Blot, protein expression in bacteria)
4. Biochemistry (Chromatography AKTA-AVANT; Fluorescence plate reader)
5. Mammalian tissue culture and viruses room (BSL 2+)



Short personal activity proposal for the COST Action CA15135 (max 1000 characters)

My have expertise in X-ray crystallography of macromolecules related to infectious pathogens and cancer, as well as in enzymatic activities and relating structure to function. Recently I proposed a novel hyothesis, viral rerouting-resistance, in which I suggest that the multiple pathways targeted by viruses must be identified and simulatneously targeted at multilevels. This COST action suggests a similar idea of developing the drugs to traget multiple targets at the same time.

Joining this COST action will expose me to the medicinal chemists society, which I am eager to collaborate and sure of fruitful outcome. I can contribute with my expertise using X-ray crystallograpy, structure-function analysis and structure-based drug desing to help increasing drug potencies.




Work Group preference: score from 1 (preferred) to 4 (not preferred)

Work Group of the CA15135 COST Action Score
WG1: Development of new chemical entities 1
WG2: Selection of biological targets and assessment of biological data 2
WG3: Development of chemical databases 4
WG4: Development of Computational methods for multiple ligand design and discovery 4